SARS-CoV-2–specific Humoral and Cellular Immunities in Kidney Transplant Recipients and Dialyzed Patients Recovered From Severe and Nonsevere COVID-19

Background. Kidney transplantation and dialysis are two major risk factors for severe forms of coronavirus disease 2019 (COVID-19). The dynamics of the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in this population remain largely unknown. Methods. We report here t...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Dominique Bertrand, MD, Mouad Hamzaoui, MD, PhD, Laurent Drouot, PhD, Julie Lamulle, MA, Mélanie Hanoy, MD, Stéphane Edet, MD, Charlotte Laurent, MD, Ludivine Lebourg, MD, Isabelle Etienne, MD, Mathilde Lemoine, MD, Frank Le Roy, MD, Dorian Nezam, MD, Eleusis Mauger, MD, Olivier Boyer, MD, PhD, Dominique Guerrot, MD, PhD, Sophie Candon, MD, PhD
Formato:	article
Lenguaje:	EN
Publicado:	Wolters Kluwer 2021
Materias:	Surgery RD1-811
Acceso en línea:	https://doaj.org/article/9036a2c630314485b4caca66a6375f22
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9036a2c630314485b4caca66a6375f22
record_format	dspace
spelling	oai:doaj.org-article:9036a2c630314485b4caca66a6375f222021-11-25T07:59:57ZSARS-CoV-2–specific Humoral and Cellular Immunities in Kidney Transplant Recipients and Dialyzed Patients Recovered From Severe and Nonsevere COVID-192373-873110.1097/TXD.0000000000001230https://doaj.org/article/9036a2c630314485b4caca66a6375f222021-12-01T00:00:00Zhttp://journals.lww.com/transplantationdirect/fulltext/10.1097/TXD.0000000000001230https://doaj.org/toc/2373-8731Background. Kidney transplantation and dialysis are two major risk factors for severe forms of coronavirus disease 2019 (COVID-19). The dynamics of the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in this population remain largely unknown. Methods. We report here the analysis of anti–SARS-CoV-2 antibody– and T cell–mediated immune responses in 26 kidney transplant recipients (KTRs) and 11 dialyzed patients (DPs) who recovered from COVID-19. Results. After a mean time of 83 ± 26 d post–symptom onset for KTRs and 97 ± 31 d for DPs, 20 KTRs (76.9%) and 10 DPs (90.9%) displayed anti-S1 immunoglobulin G SARS-CoV-2 antibodies (P = 0.34), at similar titers in both groups. SARS-CoV-2–specific interferon-γ–producing T cells were evidenced in 26 KTRs (100%) and 10 DPs (90.9%). Total numbers of SARS-CoV-2–reactive T cells were high and not statistically different between the 2 groups. No correlation between the severity of the disease and the number of reactive T cells was found in KTRs. In 5 KTRs, also evaluated 10 mo after COVID-19, weak or absent antibody response was observed, whereas specific memory T-cell response was detected in all cases. Conclusion. T-cell response persisted up to 3 mo post–symptom onset, even in KTRs in whom full immunosuppressive regimen was reinstated at recovery, and seems to be present up to 10 mo after infection. Our findings have implications in the understanding of the natural course of the disease in transplant patients and DPs.Dominique Bertrand, MDMouad Hamzaoui, MD, PhDLaurent Drouot, PhDJulie Lamulle, MAMélanie Hanoy, MDStéphane Edet, MDCharlotte Laurent, MDLudivine Lebourg, MDIsabelle Etienne, MDMathilde Lemoine, MDFrank Le Roy, MDDorian Nezam, MDEleusis Mauger, MDOlivier Boyer, MD, PhDDominique Guerrot, MD, PhDSophie Candon, MD, PhDWolters KluwerarticleSurgeryRD1-811ENTransplantation Direct, Vol 7, Iss 12, p e792 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Surgery RD1-811
spellingShingle	Surgery RD1-811 Dominique Bertrand, MD Mouad Hamzaoui, MD, PhD Laurent Drouot, PhD Julie Lamulle, MA Mélanie Hanoy, MD Stéphane Edet, MD Charlotte Laurent, MD Ludivine Lebourg, MD Isabelle Etienne, MD Mathilde Lemoine, MD Frank Le Roy, MD Dorian Nezam, MD Eleusis Mauger, MD Olivier Boyer, MD, PhD Dominique Guerrot, MD, PhD Sophie Candon, MD, PhD SARS-CoV-2–specific Humoral and Cellular Immunities in Kidney Transplant Recipients and Dialyzed Patients Recovered From Severe and Nonsevere COVID-19
description	Background. Kidney transplantation and dialysis are two major risk factors for severe forms of coronavirus disease 2019 (COVID-19). The dynamics of the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in this population remain largely unknown. Methods. We report here the analysis of anti–SARS-CoV-2 antibody– and T cell–mediated immune responses in 26 kidney transplant recipients (KTRs) and 11 dialyzed patients (DPs) who recovered from COVID-19. Results. After a mean time of 83 ± 26 d post–symptom onset for KTRs and 97 ± 31 d for DPs, 20 KTRs (76.9%) and 10 DPs (90.9%) displayed anti-S1 immunoglobulin G SARS-CoV-2 antibodies (P = 0.34), at similar titers in both groups. SARS-CoV-2–specific interferon-γ–producing T cells were evidenced in 26 KTRs (100%) and 10 DPs (90.9%). Total numbers of SARS-CoV-2–reactive T cells were high and not statistically different between the 2 groups. No correlation between the severity of the disease and the number of reactive T cells was found in KTRs. In 5 KTRs, also evaluated 10 mo after COVID-19, weak or absent antibody response was observed, whereas specific memory T-cell response was detected in all cases. Conclusion. T-cell response persisted up to 3 mo post–symptom onset, even in KTRs in whom full immunosuppressive regimen was reinstated at recovery, and seems to be present up to 10 mo after infection. Our findings have implications in the understanding of the natural course of the disease in transplant patients and DPs.
format	article
author	Dominique Bertrand, MD Mouad Hamzaoui, MD, PhD Laurent Drouot, PhD Julie Lamulle, MA Mélanie Hanoy, MD Stéphane Edet, MD Charlotte Laurent, MD Ludivine Lebourg, MD Isabelle Etienne, MD Mathilde Lemoine, MD Frank Le Roy, MD Dorian Nezam, MD Eleusis Mauger, MD Olivier Boyer, MD, PhD Dominique Guerrot, MD, PhD Sophie Candon, MD, PhD
author_facet	Dominique Bertrand, MD Mouad Hamzaoui, MD, PhD Laurent Drouot, PhD Julie Lamulle, MA Mélanie Hanoy, MD Stéphane Edet, MD Charlotte Laurent, MD Ludivine Lebourg, MD Isabelle Etienne, MD Mathilde Lemoine, MD Frank Le Roy, MD Dorian Nezam, MD Eleusis Mauger, MD Olivier Boyer, MD, PhD Dominique Guerrot, MD, PhD Sophie Candon, MD, PhD
author_sort	Dominique Bertrand, MD
title	SARS-CoV-2–specific Humoral and Cellular Immunities in Kidney Transplant Recipients and Dialyzed Patients Recovered From Severe and Nonsevere COVID-19
title_short	SARS-CoV-2–specific Humoral and Cellular Immunities in Kidney Transplant Recipients and Dialyzed Patients Recovered From Severe and Nonsevere COVID-19
title_full	SARS-CoV-2–specific Humoral and Cellular Immunities in Kidney Transplant Recipients and Dialyzed Patients Recovered From Severe and Nonsevere COVID-19
title_fullStr	SARS-CoV-2–specific Humoral and Cellular Immunities in Kidney Transplant Recipients and Dialyzed Patients Recovered From Severe and Nonsevere COVID-19
title_full_unstemmed	SARS-CoV-2–specific Humoral and Cellular Immunities in Kidney Transplant Recipients and Dialyzed Patients Recovered From Severe and Nonsevere COVID-19
title_sort	sars-cov-2–specific humoral and cellular immunities in kidney transplant recipients and dialyzed patients recovered from severe and nonsevere covid-19
publisher	Wolters Kluwer
publishDate	2021
url	https://doaj.org/article/9036a2c630314485b4caca66a6375f22
work_keys_str_mv	AT dominiquebertrandmd sarscov2specifichumoralandcellularimmunitiesinkidneytransplantrecipientsanddialyzedpatientsrecoveredfromsevereandnonseverecovid19 AT mouadhamzaouimdphd sarscov2specifichumoralandcellularimmunitiesinkidneytransplantrecipientsanddialyzedpatientsrecoveredfromsevereandnonseverecovid19 AT laurentdrouotphd sarscov2specifichumoralandcellularimmunitiesinkidneytransplantrecipientsanddialyzedpatientsrecoveredfromsevereandnonseverecovid19 AT julielamullema sarscov2specifichumoralandcellularimmunitiesinkidneytransplantrecipientsanddialyzedpatientsrecoveredfromsevereandnonseverecovid19 AT melaniehanoymd sarscov2specifichumoralandcellularimmunitiesinkidneytransplantrecipientsanddialyzedpatientsrecoveredfromsevereandnonseverecovid19 AT stephaneedetmd sarscov2specifichumoralandcellularimmunitiesinkidneytransplantrecipientsanddialyzedpatientsrecoveredfromsevereandnonseverecovid19 AT charlottelaurentmd sarscov2specifichumoralandcellularimmunitiesinkidneytransplantrecipientsanddialyzedpatientsrecoveredfromsevereandnonseverecovid19 AT ludivinelebourgmd sarscov2specifichumoralandcellularimmunitiesinkidneytransplantrecipientsanddialyzedpatientsrecoveredfromsevereandnonseverecovid19 AT isabelleetiennemd sarscov2specifichumoralandcellularimmunitiesinkidneytransplantrecipientsanddialyzedpatientsrecoveredfromsevereandnonseverecovid19 AT mathildelemoinemd sarscov2specifichumoralandcellularimmunitiesinkidneytransplantrecipientsanddialyzedpatientsrecoveredfromsevereandnonseverecovid19 AT frankleroymd sarscov2specifichumoralandcellularimmunitiesinkidneytransplantrecipientsanddialyzedpatientsrecoveredfromsevereandnonseverecovid19 AT doriannezammd sarscov2specifichumoralandcellularimmunitiesinkidneytransplantrecipientsanddialyzedpatientsrecoveredfromsevereandnonseverecovid19 AT eleusismaugermd sarscov2specifichumoralandcellularimmunitiesinkidneytransplantrecipientsanddialyzedpatientsrecoveredfromsevereandnonseverecovid19 AT olivierboyermdphd sarscov2specifichumoralandcellularimmunitiesinkidneytransplantrecipientsanddialyzedpatientsrecoveredfromsevereandnonseverecovid19 AT dominiqueguerrotmdphd sarscov2specifichumoralandcellularimmunitiesinkidneytransplantrecipientsanddialyzedpatientsrecoveredfromsevereandnonseverecovid19 AT sophiecandonmdphd sarscov2specifichumoralandcellularimmunitiesinkidneytransplantrecipientsanddialyzedpatientsrecoveredfromsevereandnonseverecovid19
_version_	1718413571607494656

SARS-CoV-2–specific Humoral and Cellular Immunities in Kidney Transplant Recipients and Dialyzed Patients Recovered From Severe and Nonsevere COVID-19

Ejemplares similares